Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

• Status: NOT_YET_RECRUITING
• Trial end date: 2033-10-03

Summary

This phase II trial compares the effect of chemotherapy (carboplatin and paclitaxel) with versus without cemiplimab given before surgery (neoadjuvant) in patients with sinonasal squamous cell cancer. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients with sinonasal squamous cell cancer is surgery followed by radiation therapy, with or without chemotherapy. Recently, some patients have also been treated with neoadjuvant chemotherapy before surgery. Adding cemiplimab to chemotherapy before surgery may be more effective at stopping the cancer from growing or spreading, compared to chemotherapy alone.

• Phase: PHASE2

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: 1,2-diaminocyclohexaneplatinum II citrate; Biopsy; Carboplatin; cemiplimab; Chemoradiotherapy; Cisplatin; Magnetic Resonance Spectroscopy; Paclitaxel; Platinum; Radiation; Radiotherapy; Specimen Handling; Surgical Procedures, Operative; Taxes